|Bid||43.27 x 800|
|Ask||47.09 x 1200|
|Day's Range||42.48 - 43.92|
|52 Week Range||27.77 - 56.75|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.45|
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.About Agios Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.ContactsInvestors: Holly Manning, 617-844-6630 Director, Investor Relations Holly.Manning@agios.comMedia: Jessica Rennekamp, 857-209-3286 Associate Director, Corporate Communications Jessica.Rennekamp@agios.com
With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Bruce Car, our Chief Scientific Officer will join for Q&A.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?